Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
Rhea-AI Summary
electroCore (Nasdaq: ECOR) announced that a review article on cervical non-invasive vagus nerve stimulation (nVNS) has been accepted by Frontiers in Neuroscience.
The article synthesizes decades of multidisciplinary evidence that cervical nVNS can activate vagal pathways without surgery and addresses skepticism about non-invasive vagal activation.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – ECOR
On the day this news was published, ECOR declined 2.13%, reflecting a moderate negative market reaction. Argus tracked a peak move of +18.7% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $85.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
ECOR is up 10.55% while closely related peers show mixed moves (e.g., NMTC up 1.17%, MODD up 5.42%, IINN down 13.64%, MYO down 3.76%). Momentum scanner peers (VVOS, NSYS, IRIX) also move in both directions, supporting a stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Conference presentation | Neutral | -8.7% | Announcement of participation and presentation at Planet MicroCap Las Vegas 2026. |
| May 13 | Clinical publication | Positive | -5.6% | JAMA Network Open publication showing added Quell therapy improved fibromyalgia outcomes. |
| May 08 | Conference presentation | Neutral | +3.1% | LD Micro Invitational XVI presentation and one-on-one investor meetings announcement. |
| May 06 | Earnings results | Positive | -5.9% | Q1 2026 results with strong sales growth, high gross margin, and reaffirmed guidance. |
| Apr 30 | Product recognition | Positive | +5.8% | TAC-STIM named national semifinalist in a National Safety Council innovation challenge. |
Recent history shows multiple instances where positive clinical or financial updates were followed by negative price reactions, while product recognition and some conference appearances coincided with gains.
Over the last several months, ECOR reported strong Q1 2026 growth with net sales of $9.6 million and reaffirmed full‑year revenue guidance, yet the stock fell after earnings. A JAMA Network Open publication on Quell for fibromyalgia also preceded a decline. By contrast, TAC-STIM’s recognition as a national semifinalist in a safety innovation challenge aligned with gains. Multiple conference presentations highlight active investor outreach. Today’s neuroscience review acceptance further builds the company’s evidence base for vagus nerve stimulation.
Regulatory & Risk Context
An effective S-3 shelf filed on Oct 03, 2025 registers up to 762,508 resale shares, including conversion and private placement shares. The company is not selling securities under this registration and will not receive proceeds from stockholder resales, though it bears registration expenses.
Market Pulse Summary
This announcement reinforces the scientific foundation for cervical nVNS, with a review in Frontiers in Neuroscience synthesizing evidence across anatomy, modeling, neuroimaging, and sham-controlled trials. It follows recent clinical publication, product recognition, and strong Q1 2026 revenue growth. Investors may watch how this growing evidence base influences adoption of ECOR’s devices, while also monitoring cash levels, ongoing losses, insider activity, and any use of registered resale shares disclosed in SEC filings.
Key Terms
non-invasive vagus nerve stimulation medical
vagus nerve medical
neuroimaging medical
electrophysiology medical
immunology medical
autonomic physiology medical
sham-controlled clinical trials medical
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for publication in Frontiers in Neuroscience.
Authored by Norianne Theresa Ingram, PhD; Colin Daniels, MD, MBA; Nina Riggins, MD, PhD; Jennifer R. Stevane, MD, FACS; and Peter S. Staats, MD, MBA; the article synthesizes decades of scientific evidence supporting the ability of cervical non-invasive vagus nerve stimulation (nVNS) to activate vagal pathways without surgical implantation.
The review evaluates evidence from anatomy, computational modeling, neuroimaging, electrophysiology, immunology, autonomic physiology, and sham-controlled clinical trials. Together, these findings support the ability of cervical nVNS to engage vagal pathways without surgical implantation and address longstanding skepticism regarding non-invasive vagal activation.
"The scientific evidence supporting non-invasive vagus nerve stimulation has grown substantially over the past two decades," said Peter S. Staats, MD, MBA, Chief Medical Officer of electroCore and co-author of the publication. "By bringing together evidence from multiple scientific disciplines, this review demonstrates that meaningful vagal engagement can be achieved without surgery and further supports cervical nVNS as a clinically validated approach to bioelectronic medicine."
The article is expected to appear in an upcoming issue of the journal. The abstract is available here.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) for primary headache conditions and Quell® Fibromyalgia for reducing symptoms of fibromyalgia, are FDA-authorized neuromodulation devices. Additionally, the Company commercializes its handheld and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the expected publication of the review article, statements from the review article supporting non-invasive vagus nerve stimulation as a meaningful form of vagal activation and the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” "may," "potential," and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to engage vagal pathways without surgical implantation, the possibility that future clinical studies may not replicate the findings discussed in the review article, the ability of the Company to develop and commercialize new products or technologies, its ability to obtain regulatory clearance or approval for new indications, changes in the regulatory environment for medical devices and general wellness products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, as well as competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
